Philippe MOREAU
Nantes University Hospital · CHU Nantes, France · University Hospital, CHU de NANTES
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Philippe MOREAU as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04934475 · MInimal Residual Disease Adapted StrategyIntergroupe Francophone du Myelome · active not recruiting · Multiple Myeloma · principal investigator
- Ph3NCT02541383 · A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaIntergroupe Francophone du Myelome · completed · Multiple Myeloma · principal investigator
- Ph3NCT01971658 · Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)Nantes University Hospital · completed · Multiple Myeloma · principal investigator
- Ph2NCT01936532 · Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)Nantes University Hospital · completed · Newly Diagnosed Multiple Myeloma · principal investigator
- N/ANCT01794572 · Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma RelapseInstitut Cancerologie de l'Ouest · terminated · Multiple Myeloma in Relapse · principal investigator
- Ph1/Ph2NCT01279694 · Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)Nantes University Hospital · completed · Myeloma · principal investigator
- Ph2NCT01053949 · IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaUniversity Hospital, Lille · completed · Multiple Myeloma · principal investigator
- N/ANCT00907452 · Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasoneIntergroupe Francophone du Myelome · completed · Myeloma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 265 PubMed records, and a shared surname and initials can bring in a namesake. All 265 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,208 citationsRCR 41.0
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med · 20151,133 citationsRCR 36.3
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20151,116 citationsRCR 34.1
- 1,045 citationsRCR 36.3
- 960 citationsRCR 25.8
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 2016873 citationsRCR 28.4
- 854 citationsRCR 35.4
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9